BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update
BERGEN, Norway, February 16, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the fourth quarter ended December 31, 2022, and provided a business update. A briefing by BerGenBio's senior management team will take place at 10:00 am CET today via a webcast presentation, followed by a Q&A session. Please see below for details. “The recent announcement of the topline data from our BCBG008 NSCLC trial corroborates the strategy we